Monocyte and lymphocyte surface molecules in severe sepsis and non-septic critically ill Patients

Apmis ◽  
2017 ◽  
Vol 125 (6) ◽  
pp. 536-543 ◽  
Author(s):  
Joel Jämsä ◽  
Hannu Syrjälä ◽  
Virva Huotari ◽  
Eeva-Riitta Savolainen ◽  
Tero Ala-Kokko
Keyword(s):  
Severe Sepsis ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Surface Molecules ◽  
Lymphocyte Surface

scholarly journals Galectin-3 in Critically Ill Patients with Sepsis and/or Trauma: A Good Predictor of Outcome or Not?

2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Jasna Jevdjic ◽  
Maja Surbatovic ◽  
Snezana Milosavljevic ◽  
Goran Rondovic ◽  
Ivan Stanojevic ◽  
...  
Keyword(s):  
Severe Sepsis ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Good Predictor ◽  
Injury Severity ◽  
Area Under The Curve ◽  
University Hospital ◽  
Youden Index ◽  
Lethal Outcome ◽  
Galectin 3

Abstract Severe sepsis and/or trauma complicated with multiple organ dysfunction syndrome are leading causes of death in critically ill patients. The aim of this prospective, observational, single centre study was to assess the prognostic value of galectin-3 regarding outcome in critically ill patients with severe trauma and/or severe sepsis. The outcome measure was hospital mortality. In total, 75 critically ill patients who were admitted to the intensive care unit of the tertiary university hospital were enrolled in a prospective observational study. Blood samples were collected upon fulfilling Sepsis-3 criteria and for a traumatized Injury Severity Score > 25 points. Levels of galectin-3 were significantly higher in nonsurvivors on the day of enrolment - Day 1 (p<0.05). On Day 1, the area under the curve (AUC) for the galectin-3 for lethal outcome was 0.602. At a cut-off level of 262.82 ng/mL, the sensitivity was 53%, and the specificity was 69.7%, which was objectively determined by a Youden index of 0.20. The discriminative power of galectin-3 in predicting outcome was statistically significant. Galectin-3 on Day 1 is a fairly good predictor of lethal outcome.

The role of neutrophil chemotaxis activity as an immunologic biomarker to predict mortality in critically-ill patients with severe sepsis

2020 ◽  
Vol 56 ◽  
pp. 215-221 ◽  
Author(s):  
Nattachai Srisawat ◽  
Win Kulvichit ◽  
Somkanya Tungsanga ◽  
Sadudee Peerapornratana ◽  
Suttinan Vorasitchai ◽  
...  
Keyword(s):  
Severe Sepsis ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Neutrophil Chemotaxis

scholarly journals Chronically critically ill patients: different behavior in severe sepsis and septic shock?

2015 ◽  
Vol 3 (S1) ◽  
Author(s):  
DH Prevedello ◽  
A Rea-Neto ◽  
HA Teive ◽  
LA Tannous ◽  
RAO Deucher ◽  
...  
Keyword(s):  
Septic Shock ◽  
Severe Sepsis ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Chronically Critically Ill ◽  
Sepsis And Septic Shock

Venous thromboembolism in critically ill patients

2009 ◽  
Vol 101 (01) ◽  
pp. 139-144 ◽  
Author(s):  
Mark Williams ◽  
Andrew Shorr
Keyword(s):  
Severe Sepsis ◽  
Venous Thromboembolism ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Controlled Trial ◽  
Double Blind ◽  
Vte Prophylaxis ◽  
Drotrecogin Alfa Activated ◽  
History Of ◽  
Sepsis And Septic Shock

SummaryVenous thromboembolism (VTE) is a central concern in the intensive care unit (ICU). However, little is known about both current practices for VTE prevention in the ICU and the risk for VTE in persons with severe sepsis and septic shock. XPRESS was a randomized, double-blind, placebo-controlled trial of prophylactic heparin in patients with severe sepsis and higher disease severity who were treated with drotrecogin alfa (activated) (DAA). Subjects were randomized to unfractionated heparin, low-molecular-weight heparin, or placebo during the DAA infusion period. All patients underwent ultrasonography between days 4-6 to screen for VTE. We assessed baseline utilization of VTE prophylaxis along with application of these methods after completion of the DAA infusion. The study included 1,935 subjects and, prior to enrollment approximately half were given no form of prophylaxis. By day 6, 5% of subjects developed a VTE, and the rate of VTE did not vary based on type of heparin administered. The vast majority of VTE detected by day 6 were clinically silent. Of factors analyzed, history of VTE was the only variable independently associated with development of a VTE (odds ratio, 3.66, 95% confidence interval 1.77–7.56, p=0.005). Strikingly, patients who were initially receiving heparin prophylaxis prior to enrollment but who then had this discontinued because of randomization to placebo suffered more VTE that persons continuing on some form of heparin. Despite multiple guidelines, physicians do not uniformly prescribe VTE prophylaxis. Nonetheless, early VTE occurs even in persons given DAA. Most VTE in critically ill patients are clinically silent.

Thrombocytopenia in critically ill patients with severe sepsis/septic shock: Prognostic value and association with a distinct serum cytokine profile

2016 ◽  
Vol 32 ◽  
pp. 9-15 ◽  
Author(s):  
Panagiotis Tsirigotis ◽  
Spiros Chondropoulos ◽  
Frantzeska Frantzeskaki ◽  
Maria Stamouli ◽  
Konstantinos Gkirkas ◽  
...  
Keyword(s):  
Septic Shock ◽  
Severe Sepsis ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Prognostic Value ◽  
Cytokine Profile ◽  
Serum Cytokine

Early enteral immunonutrition vs. parenteral nutrition in critically ill patients without severe sepsis: a randomized clinical trial

2006 ◽  
Vol 32 (8) ◽  
pp. 1191-1198 ◽  
Author(s):  
D. Radrizzani ◽  
G. Bertolini ◽  
R. Facchini ◽  
B. Simini ◽  
P. Bruzzone ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Severe Sepsis ◽  
Parenteral Nutrition ◽  
Randomized Clinical Trial ◽  
Critically Ill ◽  
Critically Ill Patients

scholarly journals Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem during the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units

2015 ◽  
Vol 59 (6) ◽  
pp. 2995-3001 ◽  
Author(s):  
Sutep Jaruratanasirikul ◽  
Suriyan Thengyai ◽  
Wibul Wongpoowarak ◽  
Thitima Wattanavijitkul ◽  
Kanyawisa Tangkitwanitjaroen ◽  
...  
Keyword(s):  
Septic Shock ◽  
Monte Carlo ◽  
Severe Sepsis ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Early Phase ◽  
Volume Of Distribution ◽  
Therapeutic Success ◽  
Altered Pharmacokinetic ◽  
Sepsis And Septic Shock

ABSTRACTPathophysiological changes during the early phase of severe sepsis and septic shock in critically ill patients, resulting in altered pharmacokinetic (PK) patterns for antibiotics, are important factors influencing therapeutic success. The aims of this study were (i) to reveal the population PK parameters and (ii) to assess the probability of target attainment (PTA) for meropenem. The PK studies were carried out following administration of 1 g of meropenem every 8 h during the first 24 h of severe sepsis and septic shock in nine patients, and a Monte Carlo simulation was performed to determine the PTA of achieving 40% exposure time during which the free plasma drug concentration remains above the MIC (fT>MIC) and 80%fT>MIC. The volume of distribution (V) and total clearance (CL) of meropenem in these patients were 23.7 liters and 7.82 liters/h, respectively. For pathogens with MICs of 4 μg/ml, the PTAs of 40%fT>MICfollowing administration of meropenem as a 1-h infusion of 1 g every 8 h and a 4-h infusion of 0.5 g every 8 h were 92.52% and 90.29%, respectively. For pathogens with MICs of 2 μg/ml in immunocompromised hosts, the PTAs of 80%fT>MICfollowing administration of 1-h and 4-h infusions of 2 g of meropenem every 8 h were 84.32% and 94.72%, respectively. These findings indicated that theVof meropenem was greater and the CL of meropenem was lower than the values obtained in a previous study with healthy subjects. The maximum recommended dose, i.e., 2 g of meropenem every 8 h, may be required for treatment of life-threatening infections in this patient population.

Sign in / Sign up

Export Citation Format

Share Document